Adare Pharma Appoints Joseph Del Buono As Vice President, Finance And Chief Financial Officer

PRINCETON, New Jersey, August 26, 2015 - Adare Pharmaceuticals, Inc., formerly Aptalis Pharmaceutical Technologies, announced today that Joseph (Joe) Del Buono has joined the Company as Vice President, Finance and Chief Financial Officer. He will be based at the Company's headquarters in Princeton, NJ.

"We are pleased to have Joe join our team as our CFO. His extensive background in pharmaceutical finance will bring enormous benefits to our organization as we implement our growth plans," said John Fraher, President and CEO of Adare Pharmaceuticals.

Mr. Del Buono will help drive Adare's growth by building out the finance function and establishing the financial infrastructure to support the Company's multinational operations. He will also provide financial oversight and guidance on Adare's operations and growth opportunities.

Mr. Del Buono brings almost 20 years of finance experience within the pharmaceutical and biotechnology industry. He comes to Adare from Aphena Pharma Solutions where he served as Corporate Vice President, Chief Financial Officer since 2011. Previously, he held a number of senior finance positions for Alpharma/King Pharmaceuticals, Sun Chemical and Schering-Plough. He began his career in the audit and business advisory practice of Arthur Andersen & Co.

Mr. Del Buono holds a BA in Accounting from Rutgers University and is a CPA.

About Adare Pharmaceuticals

Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health. For decades, the company has solved complex formulation, manufacturing and commercialization challenges, resulting in transformational medicines that deliver value to all its stakeholders. Adare Pharmaceuticals has a global presence with R&D, manufacturing and commercial operations in the Unites States, Europe and Canada. For more information, visit www.adarepharma.com.

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

The 100 largest companies trading on the London Stock Exchange have boosted the percentage of women on their boards, but has life sciences kept pace?

In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets.